Qiagen NV (QGEN)
42.28
-0.35
(-0.82%)
USD |
NYSE |
Nov 14, 12:18
Qiagen Revenue (Quarterly): 496.35M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 496.35M |
| March 31, 2024 | 458.80M |
| December 31, 2023 | 509.16M |
| September 30, 2023 | 475.89M |
| June 30, 2023 | 494.86M |
| March 31, 2023 | 485.40M |
| December 31, 2022 | 497.98M |
| September 30, 2022 | 499.63M |
| June 30, 2022 | 515.51M |
| March 31, 2022 | 628.39M |
| December 31, 2021 | 582.40M |
| September 30, 2021 | 534.74M |
| June 30, 2021 | 567.31M |
| March 31, 2021 | 567.21M |
| December 31, 2020 | 571.23M |
| September 30, 2020 | 483.76M |
| June 30, 2020 | 443.25M |
| March 31, 2020 | 372.10M |
| December 31, 2019 | 413.47M |
| September 30, 2019 | 382.69M |
| June 30, 2019 | 381.61M |
| March 31, 2019 | 348.65M |
| December 31, 2018 | 403.17M |
| September 30, 2018 | 377.91M |
| June 30, 2018 | 377.20M |
| Date | Value |
|---|---|
| March 31, 2018 | 343.57M |
| December 31, 2017 | 396.86M |
| September 30, 2017 | 363.98M |
| June 30, 2017 | 348.99M |
| March 31, 2017 | 307.71M |
| December 31, 2016 | 366.52M |
| September 30, 2016 | 338.68M |
| June 30, 2016 | 334.41M |
| March 31, 2016 | 298.38M |
| December 31, 2015 | 348.54M |
| September 30, 2015 | 314.56M |
| June 30, 2015 | 319.46M |
| March 31, 2015 | 298.43M |
| December 31, 2014 | 360.41M |
| September 30, 2014 | 336.46M |
| June 30, 2014 | 330.84M |
| March 31, 2014 | 317.07M |
| December 31, 2013 | 361.08M |
| September 30, 2013 | 322.11M |
| June 30, 2013 | 315.21M |
| March 31, 2013 | 303.58M |
| December 31, 2012 | 346.53M |
| September 30, 2012 | 304.29M |
| June 30, 2012 | 307.21M |
| March 31, 2012 | 296.42M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
372.10M
Minimum
Mar 2020
628.39M
Maximum
Mar 2022
505.13M
Average
497.98M
Median
Dec 2022
Revenue (Quarterly) Benchmarks
| LENZ Therapeutics Inc | -- |
| Oruka Therapeutics Inc | -- |
| Boston Scientific Corp | 4.209B |
| uniQure NV | 2.287M |
| ProQR Therapeutics NV | 6.789M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -183.46M |
| Total Expenses (Quarterly) | 656.70M |
| EPS Diluted (Quarterly) | -0.83 |
| Enterprise Value | 9.986B |
| Gross Profit Margin (Quarterly) | 7.00% |
| Profit Margin (Quarterly) | -36.96% |
| Earnings Yield | 0.75% |
| Operating Earnings Yield | 1.76% |
| Normalized Earnings Yield | 1.550 |